Arcus Biosciences, Inc. Profile Avatar - Palmy Investing

Arcus Biosciences, Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 cl…

Biotechnology
US, Hayward [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Download
Cash Amount Pay Date
Download
Cash Amount Pay Date
End of RCUS's Analysis
CIK: 1724521 CUSIP: 03969F109 ISIN: US03969F1093 LEI: - UEI: -
Secondary Listings
RCUS has no secondary listings inside our databases.